arthyperАртериальная гипертензия"Arterial’naya Gipertenziya" ("Arterial Hypertension")1607-419X2411-8524Antihypertensive League10.18705/1607-419X-2003-9-5-167-171arthyper-890Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL ARTICLESВлияние индапамида ретард на процессы сердечно-сосудистого ремоделирования у пациентов с артериальной гипертониейEffects of indapamid retard on cardiovascular remodeling processes in patients with arterial hypertensionИваненкоВ. В.IvanenkoV. V.noemail@neicon.ruСеменоваН. В.SemenovaN. V.noemail@neicon.ruРязанцеваН. В.RyazancevaN. V.noemail@neicon.ruЛегкийА. В.LegkiyA. V.noemail@neicon.ruАнисимоваЛ. П.AnisimovaI. P.noemail@neicon.ruЛопатинЮ. М.LopatinYu. M.noemail@neicon.ruВолгоградский государственный медицинский университет; Волгоградский областной кардиологический центрRussian Federation20032810200395167171Copyright © Иваненко В.В., Семенова Н.В., Рязанцева Н.В., Легкий А.В., Анисимова Л.П., Лопатин Ю.М., 20032003Иваненко В.В., Семенова Н.В., Рязанцева Н.В., Легкий А.В., Анисимова Л.П., Лопатин Ю.М.Ivanenko V.V., Semenova N.V., Ryazanceva N.V., Legkiy A.V., Anisimova I.P., Lopatin Y.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://htn.almazovcentre.ru/jour/article/view/890

Целью исследования явилось изучение влияния тиазидоподобного диуретика индапамида ретард на процессы сердечно-сосудистого ремоделирования у пациентов с артериальной гипертонией. В исследование были включены 20 ранее не леченных пациентов с артериальной гипертонией I-II степени (средний возраст 51,7 ± 2,7 года) и давностью заболевания от 2 до 6 лет. Длительность терапии индапамидом ретард составила 6 месяцев. Было установлено, что у больных артериальной гипертонией терапия андапамидом ретард приводит к снижению массы миокарда левого желудочка и увеличению числа пациентов артериальной гипертонией с нормальной геометрией левого желудочка. Также продемонстрировано достоверное снижение скорости пульсовой волны прежде всего в артериях эластичного типа. Индапамид ретард, обладая выскокой антигипертензивной эффективностью, отличной переносимостью и метаболической нейтральностью, оказывал значимое положительное влияние на процессы ремоделирования как сердца, так и крупных и средних артерий у больных артериальной гипертонией.

The aim of this study was to evaluate the effect of the thiazide-like diuretic indapamid retard on cardiovascular remodeling processes in patients with arterial hypertension. The study included 20 previously untreated patients (mean age 51,7 ± 2,7 years) with Stages I - П arterial hypertension and a disease history of 2 to 6 years. The duration of indapamid retard therapy was 2 to 6 months. In patients with arterial hypertension, indapamid retard therapy leads to a decrease in left ventricular myocardial weight and to a larger number of more patients with arterial hypertension with the normal geometry of the left ventricle. There was a significant decrease in the rale of pulse wave primarily in the arteries of elastic type. By having a high antihypertensive efficacy, excellent tolerance, metabolic neutrality, indapamid retard produced a significant effect on remodeling processes of the heart, large and middle arteries in patients with arterial hypertension.

сердечно-сосудистое ремоделированиеартериальная гипертонияиндапамид ретардKeys words: cardiovascular remodelingarterial hypertensionindapamid retardReferencesGuidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-53.Guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-53.Cucpidi C., Ambrosioni E., Mancia G., Pessina A.C., Trimarco B., Zanchetti A.; APROS Investigators. Role of echocardiography and carotid ultrasonography in stratifying risk in patients with essential hypertension: the Assessment of Prognostic Risk Observational Survey. J Hypertens. 2002 Jul;2 0(7): 1307-14.Cucpidi C., Ambrosioni E., Mancia G., Pessina A.C., Trimarco B., Zanchetti A.; APROS Investigators. Role of echocardiography and carotid ultrasonography in stratifying risk in patients with essential hypertension: the Assessment of Prognostic Risk Observational Survey. J Hypertens. 2002 Jul;2 0(7): 1307-14.Gosse P., Sheridan D.J., Zannad F., Duborg O., Gueret P., Karpov Y., de Leeuw P.W., Palma-Gamiz J.L., Pessina A., Motz W., Degaute J.P., Chastang C. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg: the LIVE study. J Hypertens. 2000 Oct; 18 (10): 1465-75.Gosse P., Sheridan D.J., Zannad F., Duborg O., Gueret P., Karpov Y., de Leeuw P.W., Palma-Gamiz J.L., Pessina A., Motz W., Degaute J.P., Chastang C. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg: the LIVE study. J Hypertens. 2000 Oct; 18 (10): 1465-75.Terpstra W.F., May J.F., Smit A.J., de Graeff P.A., Havinga T.K., van den Veur E., Schurman F.Y., Meyboom-de Jong B., Crijns H.J. Long-term effects of amlodipine and lisinopril on left ventricular mass and diastolic function in elderly, previously untreated hypertensive patients: the ELVERA trial. J Hypertens. 2001 Feb; 19 (2): 303-9.Terpstra W.F., May J.F., Smit A.J., de Graeff P.A., Havinga T.K., van den Veur E., Schurman F.Y., Meyboom-de Jong B., Crijns H.J. Long-term effects of amlodipine and lisinopril on left ventricular mass and diastolic function in elderly, previously untreated hypertensive patients: the ELVERA trial. J Hypertens. 2001 Feb; 19 (2): 303-9.Devereux R.B., Palmieri V., Sharpe N., De Quattro V., Bella J.N., de Simone G., Walker J.F., Hahn R.T., Dahlof B. Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: the prospective randomized enalapril study evaluating regression of ventricular enlargement (preserve) trial. Circulation. 2001 Sep 11; 104 (11): 1248-54.Devereux R.B., Palmieri V., Sharpe N., De Quattro V., Bella J.N., de Simone G., Walker J.F., Hahn R.T., Dahlof B. Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: the prospective randomized enalapril study evaluating regression of ventricular enlargement (preserve) trial. Circulation. 2001 Sep 11; 104 (11): 1248-54.Cuspidi C., Muiesan M.L., Valagussa L., Salvetti M., Di Biagio C., Agabiti Rosei E., Magnani B., Zanchetti A.; CATCH investigators. Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study. J Hypertens. 2002 Nov; 20 (11): 2293-300.Cuspidi C., Muiesan M.L., Valagussa L., Salvetti M., Di Biagio C., Agabiti Rosei E., Magnani B., Zanchetti A.; CATCH investigators. Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study. J Hypertens. 2002 Nov; 20 (11): 2293-300.Zanchetti A., Bond M.G., Henning M., Neiss A., Mancia G., Dal Palu C., Hansson L., Magnani B., Rahn K.H., Reid J.L., Rodicio J., Sarar M., Eckes L., Ruzzini P.; European Lacidipine Study on Atherosclerosis investigators. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation. 2002 Nov 5; 106 (19): 2422-7.Zanchetti A., Bond M.G., Henning M., Neiss A., Mancia G., Dal Palu C., Hansson L., Magnani B., Rahn K.H., Reid J.L., Rodicio J., Sarar M., Eckes L., Ruzzini P.; European Lacidipine Study on Atherosclerosis investigators. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation. 2002 Nov 5; 106 (19): 2422-7.Devereux R.B., Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation. 1977 Apr; 55 (4): 613-8.Devereux R.B., Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation. 1977 Apr; 55 (4): 613-8.De Simone G., Daniels S.R., Devereux R.B., Meyer R.A., Roman M.J., de Devetiis O., Alderman M.H. Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and impact of overweight. J Am Coll Cardiol. 1992 Nov 1; 20 (5): 1251-60.De Simone G., Daniels S.R., Devereux R.B., Meyer R.A., Roman M.J., de Devetiis O., Alderman M.H. Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and impact of overweight. J Am Coll Cardiol. 1992 Nov 1; 20 (5): 1251-60.Недогода С.В., Лопатин Ю.М., Чаляби Т.А и соавт. Изменения скорости распространения пульсовой волны при артериальной гипертензии. Южно-Российский Мед. Журн. 2002; 3: 39-42.Недогода С.В., Лопатин Ю.М., Чаляби Т.А и соавт. Изменения скорости распространения пульсовой волны при артериальной гипертензии. Южно-Российский Мед. Журн. 2002; 3: 39-42.Zanchetti A., Ruilope L.M., Cuspidi C. et al. Comparative effects of the ACE ihibitor fosinopril and the calcium antagonist amlodipine on left ventricular hypertrophy and urinary albumin excretion in hypertensive patients. Results of POAM, a milticenter European study. J Hypertens 2001; 19 (suppl. 2): S92.Zanchetti A., Ruilope L.M., Cuspidi C. et al. Comparative effects of the ACE ihibitor fosinopril and the calcium antagonist amlodipine on left ventricular hypertrophy and urinary albumin excretion in hypertensive patients. Results of POAM, a milticenter European study. J Hypertens 2001; 19 (suppl. 2): S92.Laurent S., Lacolley P.M., Cuche J.L., Safar M.E. Influence of diuretics on brachial artery diameter and distensibility in hypertensive patients. Fundam Clin Pharmacol. 1990; 4 (6): 685-93.Laurent S., Lacolley P.M., Cuche J.L., Safar M.E. Influence of diuretics on brachial artery diameter and distensibility in hypertensive patients. Fundam Clin Pharmacol. 1990; 4 (6): 685-93.Asmar R.G., Benetos A., Chaouche-Teyara K., Reveau-Landon C.M., Safar M.E. Comparison of effects of felodipine versus hydrochlorothiazide on arterial diameter and pulse-wave velocity in essential hypertension. Am J Cardiol. 1993 Oct 1; 72 (11): 794-8.Asmar R.G., Benetos A., Chaouche-Teyara K., Reveau-Landon C.M., Safar M.E. Comparison of effects of felodipine versus hydrochlorothiazide on arterial diameter and pulse-wave velocity in essential hypertension. Am J Cardiol. 1993 Oct 1; 72 (11): 794-8.Benetos A., Lafleche A., Asmar R., Gautier S., Safar A., Safar M.E. Arterial stiffness, hydrochlorothiazide and converting enzyme inhibition in essential hypertension. J Hum Hypertens. 1996 Feb; 10 (2): 77-82.Benetos A., Lafleche A., Asmar R., Gautier S., Safar A., Safar M.E. Arterial stiffness, hydrochlorothiazide and converting enzyme inhibition in essential hypertension. J Hum Hypertens. 1996 Feb; 10 (2): 77-82.

The authors declare that there are no conflicts of interest present.